株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Teva Pharmaceutical Industries Limitedの製品パイプライン分析

Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 224553
出版日 ページ情報 英文 150 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
Teva Pharmaceutical Industries Limitedの製品パイプライン分析 Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2016
出版日: 2016年02月29日 ページ情報: 英文 150 Pages
概要

Teva Pharmaceutical Industries Limitedは、ジェネリックおよびブランド医薬品の開発、製造、販売を行う世界的な製薬企業です。

当レポートでは、Teva Pharmaceutical Industries Limitedにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Teva Pharmaceutical Industries Limitedの基本情報

Teva Pharmaceutical Industries Limitedの概要

  • 主要情報
  • 企業情報

Teva Pharmaceutical Industries Limited:R&Dの概要

  • 主な治療範囲

Teva Pharmaceutical Industries Limited:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • 併用療法モダリティ
  • パートナー製品
  • アウトライセンス製品

Teva Pharmaceutical Industries Limited:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
  • 治験段階にあるパイプライン製品
  • 初期段階にあるパイプライン製品

Teva Pharmaceutical Industries Limited:開発段階が不明のパイプライン製品

Teva Pharmaceutical Industries Limited:薬剤プロファイル

  • balugrastim
  • laquinimod sodium
  • lipegfilgrastim
  • DR-2011
  • armodafinil
  • beclomethasone dipropionate
  • bendamustine
  • custirsen sodium
  • hydrocodone bitartrate ER
  • Leukocyte Interleukin Injection
  • pridopidine
  • reslizumab
  • pagoclone
  • mercaptopurine DR
  • omacetaxine mepesuccinate
  • TV-1106
  • TV-1380
  • TV-45070
  • CEP-32496
  • CEP-37250
  • CEP-37440
  • CEP-9722
  • glatiramer acetate
  • irdabisant
  • rasagiline
  • XMT-1107
  • CEP-11981
  • CEP-28122
  • CEP-33779
  • CEP-37248
  • CEP-40783
  • NP-201
  • NP-202
  • AD-3
  • AD-4
  • HIV治療用の多剤混合薬
  • 中枢神経系疾患治療用の小分子
  • 依存症治療薬
  • パーキンソン病治療薬
  • risperidone LAI、など

Teva Pharmaceutical Industries Limited:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Teva Pharmaceutical Industries Limited:最近のパイプライン動向

Teva Pharmaceutical Industries Limited:休止中のプロジェクト

Teva Pharmaceutical Industries Limited:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル

Teva Pharmaceutical Industries Limited:企業発表

Teva Pharmaceutical Industries Limited:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07979CDB

Summary

Global Markets Direct's, 'Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2016', provides an overview of the Teva Pharmaceutical Industries Limited's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Teva Pharmaceutical Industries Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Teva Pharmaceutical Industries Limited
  • The report provides overview of Teva Pharmaceutical Industries Limited including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Teva Pharmaceutical Industries Limited's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Teva Pharmaceutical Industries Limited's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Teva Pharmaceutical Industries Limited's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Teva Pharmaceutical Industries Limited
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Teva Pharmaceutical Industries Limited's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Teva Pharmaceutical Industries Limited Snapshot
    • Teva Pharmaceutical Industries Limited Overview
    • Key Information
    • Key Facts
  • Teva Pharmaceutical Industries Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Teva Pharmaceutical Industries Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • Teva Pharmaceutical Industries Limited - Pipeline Products Glance
  • Teva Pharmaceutical Industries Limited - Late Stage Pipeline Products
  • Teva Pharmaceutical Industries Limited - Clinical Stage Pipeline Products
  • Teva Pharmaceutical Industries Limited - Early Stage Pipeline Products
  • Teva Pharmaceutical Industries Limited - Unknown Stage Pipeline Products
  • Teva Pharmaceutical Industries Limited - Drug Profiles
    • (fluticasone propionate + salmeterol xinafoate)
    • deutetrabenazine ER
    • hydrocodone bitartrate ER
    • laquinimod sodium
    • reslizumab
    • omacetaxine mepesuccinate
    • (acetaminophen + hydrocodone bitartarate) IR
    • armodafinil
    • beclomethasone dipropionate
    • bendamustine hydrochloride
    • fluticasone propionate
    • rasagiline mesylate
    • TEV-48125
    • funapide
    • pridopidine hydrochloride
    • TV-1380
    • (acetaminophen + oxycodone hydrochloride) IR
    • (fluticasone propionate + salmeterol xinafoate) MDI
    • CEP-37440
    • glatiramer acetate
    • SD-560
    • TEV-48107
    • TEV-90110
    • TEV-90111
    • TEV-90112
    • TEV-90113
    • TV-44664
    • atropine sulfate
    • CEP-11981
    • CEP-28122
    • CEP-33779
    • Drug for Undisclosed Indication
    • NIB-2
    • NP-201
    • NP-202
    • Recombinant Protein to Inhibit IL-17A for Psoriasis
    • Recombinant Protein to Target CD38 for Multiple Myeloma
    • SD-1077
    • Small Molecule 2 to Antagonize 5-HT6 for CNS Disorders
    • Small Molecule to Antagonize NMDA Receptor for Undisclosed Indication
    • Small Molecule to Inhibit CGRP for Migraine
    • Small Molecules to Inhibit DAT for Sleep Disorders
    • (acetaminophen + immediate release opioid 1)
    • (acetaminophen + immediate release opioid 2)
    • AD-3
    • AD-4
    • Fixed Dose Combination 3 for HIV
    • Fixed Dose Combination 4 for HIV
    • Small Molecule 1 to Antagonize 5-HT6 Receptor for CNS Disorders
    • Small Molecule to Inhibit PARP-1
    • Drug for Dependence
    • Drug for Parkinson's Disease
    • risperidone LAI
  • Teva Pharmaceutical Industries Limited - Pipeline Analysis
    • Teva Pharmaceutical Industries Limited - Pipeline Products by Target
    • Teva Pharmaceutical Industries Limited - Pipeline Products by Route of Administration
    • Teva Pharmaceutical Industries Limited - Pipeline Products by Molecule Type
    • Teva Pharmaceutical Industries Limited - Pipeline Products by Mechanism of Action
  • Teva Pharmaceutical Industries Limited - Recent Pipeline Updates
  • Teva Pharmaceutical Industries Limited - Dormant Projects
  • Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products
  • Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • Teva Pharmaceutical Industries Limited - Company Statement
  • Teva Pharmaceutical Industries Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Teva Pharmaceutical Industries Limited, Key Information
  • Teva Pharmaceutical Industries Limited, Key Facts
  • Teva Pharmaceutical Industries Limited - Pipeline by Indication, 2016
  • Teva Pharmaceutical Industries Limited - Pipeline by Stage of Development, 2016
  • Teva Pharmaceutical Industries Limited - Monotherapy Products in Pipeline, 2016
  • Teva Pharmaceutical Industries Limited - Combination Treatment Modalities in Pipeline, 2016
  • Teva Pharmaceutical Industries Limited - Partnered Products in Pipeline, 2016
  • Teva Pharmaceutical Industries Limited - Partnered Products/ Combination Treatment Modalities, 2016
  • Teva Pharmaceutical Industries Limited - Out-Licensed Products in Pipeline, 2016
  • Teva Pharmaceutical Industries Limited - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Teva Pharmaceutical Industries Limited - Pre-Registration, 2016
  • Teva Pharmaceutical Industries Limited - Filing rejected/Withdrawn, 2016
  • Teva Pharmaceutical Industries Limited - Phase III, 2016
  • Teva Pharmaceutical Industries Limited - Phase II, 2016
  • Teva Pharmaceutical Industries Limited - Phase I, 2016
  • Teva Pharmaceutical Industries Limited - Preclinical, 2016
  • Teva Pharmaceutical Industries Limited - Discovery, 2016
  • Teva Pharmaceutical Industries Limited - Unknown, 2016
  • Teva Pharmaceutical Industries Limited - Pipeline by Target, 2016
  • Teva Pharmaceutical Industries Limited - Pipeline by Route of Administration, 2016
  • Teva Pharmaceutical Industries Limited - Pipeline by Molecule Type, 2016
  • Teva Pharmaceutical Industries Limited - Pipeline Products by Mechanism of Action, 2016
  • Teva Pharmaceutical Industries Limited - Recent Pipeline Updates, 2016
  • Teva Pharmaceutical Industries Limited - Dormant Developmental Projects,2016
  • Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products, 2016
  • Teva Pharmaceutical Industries Limited, Other Locations
  • Teva Pharmaceutical Industries Limited, Subsidiaries

List of Figures

  • Teva Pharmaceutical Industries Limited - Pipeline by Top 10 Indication, 2016
  • Teva Pharmaceutical Industries Limited - Pipeline by Stage of Development, 2016
  • Teva Pharmaceutical Industries Limited - Monotherapy Products in Pipeline, 2016
  • Teva Pharmaceutical Industries Limited - Combination Treatment Modalities in Pipeline, 2016
  • Teva Pharmaceutical Industries Limited - Partnered Products in Pipeline, 2016
  • Teva Pharmaceutical Industries Limited - Out-Licensed Products in Pipeline, 2016
  • Teva Pharmaceutical Industries Limited - Pipeline by Top 10 Target, 2016
  • Teva Pharmaceutical Industries Limited - Pipeline by Route of Administration, 2016
  • Teva Pharmaceutical Industries Limited - Pipeline by Molecule Type, 2016
  • Teva Pharmaceutical Industries Limited - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top